Although the consequences of RRS1 overexpression on the regulation of ribosome biogenesis per se was not determined, other reports showing that high RRS1 is oncogenic in breast [101,102], thyroid [103], and liver [104] cancers, clearly indicate that RRS1 represents a new promising target to be considered in CRC therapy. Here, RRS1 is linked to cancer.